Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-303
- Development stage
- Phase 2
- Lead developer
- Moogene Medi
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Topical
01
Overview
AD-303 (also known as HUTERA D) is a topical lipid nanoparticle (LNP) formulation of the 5-alpha reductase inhibitor dutasteride, being developed for the treatment of androgenetic alopecia (male pattern hair loss). Developed by Moogene Medi in collaboration with Addpharma, Yuhan, JW Shinyak, Medica Korea, and Chong Kun Dang, AD-303 utilizes Moogene Medi's proprietary LNP drug delivery system to effectively deliver dutasteride directly to hair follicles and scalp tissues. This localized delivery is designed to selectively lower dihydrotestosterone (DHT) levels in the scalp while minimizing systemic exposure and the associated side effects of oral dutasteride, such as sexual dysfunction and liver toxicity. The candidate is currently in Phase 1/2a clinical development in South Korea.
- Brand names
- HuteraHutera D
- Other names
- dutasteride topicaltopical dutasteride
02
Targets
SRD5A1 (Steroid 5-alpha-reductase type 1)SRD5A2 (Steroid 5-alpha-reductase type II)
Beyond the preview
Go deeper on AD-303.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-303.